Physician profile
Jagdeep Singh
NPI 1437195682
$15,020.93
in general payments reported to CMS, 2019-2025
26 companies · $7,300 in 2025
The $7,300 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $648 · 2021: $4,269 · 2022: $198 · 2023: $533 · 2024: $962 · 2025: $7,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,930 · Food and Beverage: $3,384 · Travel and Lodging: $1,482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,929.50 |
| Food and Beverage | $3,384.19 |
| Travel and Lodging | $1,481.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $5,983.39 | 2024-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $4,638.64 | 2019-2021 | |
| Abbott Laboratories | $1,253.42 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $477.92 | 2022-2025 | Wegovy, Ozempic, Saxenda |
| Boston Scientific Corporation | $470.80 | 2023-2025 | Lux-Dx Insertable Cardiac Monitor, General - Biliary Devices, Patientcare Link |
| Abbvie INC. | $446.13 | 2022-2024 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $304.06 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $247.90 | 2023-2024 | |
| Amgen INC. | $242.99 | 2024-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $239.96 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $177.78 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.53 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Horizon Therapeutics Plc | $95.64 | 2023 | Krystexxa |
| Xeris Pharmaceuticals, INC. | $64.23 | 2025 | Gvoke Hypopen |
| Lexicon Pharmaceuticals, INC. | $39.06 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $32.30 | 2020 | |
| Biohorizons Implant Systems INC. | $24.64 | 2019 | |
| Azurity Pharmaceuticals, INC. | $22.27 | 2025 | Danziten |
| Glaxosmithkline, LLC. | $22.17 | 2025 | Trelegy Ellipta |
| Phadia US INC. | $20.62 | 2025 | Immunocap |
| Acrotech Biopharma INC. | $19.66 | 2025 | Beleodaq |
| E.R. Squibb & Sons, L.L.C. | $16.65 | 2025 | Eliquis |
| Globus Medical, INC. | $16.47 | 2025 | Senza |
| Astellas Pharma US INC | $16.42 | 2024 | Veozah |
| Currax Pharmaceuticals LLC | $15.20 | 2023 | Contrave |
| Phathom Pharmaceuticals, INC. | $15.08 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jagdeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.